Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation

Division of Cardiology, Heart Institute and Department of Medicine, Cedars-Sinai Medical Center, 444 S. San Vicente Blvd., Los Angeles, CA 90048, USA.
Menopause (New York, N.Y.) (Impact Factor: 2.81). 04/2011; 18(9):943-50. DOI: 10.1097/gme.0b013e3182113672
Source: PubMed

ABSTRACT The aim of this study was to assess the relationship of the timing of hormone therapy (HT) use with angiographic coronary artery disease (CAD) and cardiovascular disease (CVD) events in women with natural versus surgical menopause.
We studied 654 postmenopausal women undergoing coronary angiography for the evaluation of suspected ischemia. Timing and type of menopause, HT use, and quantitative angiographic evaluations were obtained at baseline, and the women were followed for a median of 6 years for CVD events.
Ever users of HT had a significantly lower prevalence of obstructive CAD compared with never users (age-adjusted odds ratio, 0.41 [0.28-0.60]). Women with natural menopause initiating HT before age 55 years had lower CAD severity compared with never users (age-adjusted β [SE] = -6.23 [1.50], P < 0.0001), whereas those initiating HT at age 55 years or more did not differ statistically from never users (-3.34 [2.13], P = 0.12). HT use remained a significant predictor of obstructive CAD when adjusted for a "healthy user" model (odds ratio, 0.44 [0.30-0.73]; P = 0.002). An association between HT and fewer CVD events was observed only in the natural menopause group (hazard ratio [95% CI], 0.60 [0.41-0.88]; P = 0.009) but became nonsignificant when adjusted for the presence or severity of obstructive CAD.
Using the quantitative measurements of the timing and type of menopause and HT use, earlier initiation of HT was associated with less angiographic CAD in women with natural but not surgical menopause. Our data suggest that the effect of HT use on reduced cardiovascular event rates is mediated by the presence or absence of angiographic obstructive atherosclerosis.

Download full-text


Available from: George Sopko, Aug 23, 2015
  • Source
    • "Also in the WHI, women 50 to 59 years old receiving estrogen had less calcified-plaque burden in their coronary arteries compared with placebo (Manson et al., 2007). A more recent case control study also suggested that early initiation of HT reduced the prevalence of abnormal coronary angiograms (Shufelt et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The American Society for Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE) are the two largest societies in the world whose members comprise the major experts and professionals working in the field of reproductive medicine and embryology. These societies have never before had a joint scientific meeting. METHOD(S): A 3-day meeting was planned and took place in March of 2012. The goal was to present and debate key topics, as well as modes of practice in reproductive medicine and to discuss recent developments in the field. RESULT(S): Presentations by members of ASRM and ESHRE were of three types: 'state of the art' lectures, 'back-to-back' presentations of two points of view and debates. CONCLUSION(S): For the first time, ASRM and ESHRE held a joint meeting where a special emphasis was given to presentations on the hottest topics in the field. Although different opinions and approaches sometimes exist on the two sides of the Atlantic, an appreciation and acceptance of these differences was evident, and there was more commonality than divergence of opinion.
    Fertility and sterility 10/2012; 98(6). DOI:10.1016/j.fertnstert.2012.07.1164 · 4.59 Impact Factor
  • Source
    • "They found that naturally menopausal women who initiated HT before the age of 55 had less severe coronary artery disease than never users, and this effect was not observed in naturally menopausal women who initiated HT at or after the age of 55 [155], another result consistent with the critical period hypothesis. Furthermore, WISE researchers suggested that these conclusions were only valid in the event that the HT user was healthy with little or no pre-existing coronary artery atherosclerosis, which is also consistent with the healthy cell bias of E2 replacement [155]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: 17β-Estradiol (estradiol or E2) is implicated as a neuroprotective factor in a variety of neurodegenerative disorders. This review focuses on the mechanisms underlying E2 neuroprotection in cerebral ischemia, as well as emerging evidence from basic science and clinical studies, which suggests that there is a "critical period" for estradiol's beneficial effect in the brain. Potential mechanisms underlying the critical period are discussed, as are the neurological consequences of long-term E2 deprivation (LTED) in animals and in humans after natural menopause or surgical menopause. We also summarize the major clinical trials concerning postmenopausal hormone therapy (HT), comparing their outcomes with respect to cardiovascular and neurological disease and discussing their relevance to the critical period hypothesis. Finally, potential caveats, controversies and future directions for the field are highlighted and discussed throughout the review.
    Frontiers in Neuroendocrinology 11/2011; 33(1):85-104. DOI:10.1016/j.yfrne.2011.10.001 · 7.58 Impact Factor
  • Menopause (New York, N.Y.) 09/2011; 18(9):935-6. DOI:10.1097/gme.0b013e318227f337 · 2.81 Impact Factor
Show more